Glass House Brands (GLAS) Total Current Liabilities (2020 - 2026)
Glass House Brands' (GLAS) quarterly Total Current Liabilities came in at $40.2 million in Q1 2026, up 5.89% year-on-year from $38.0 million in Q1 2025, and up 5.92% on a QoQ basis from $38.0 million in Q4 2025.
Glass House Brands (GLAS) Total Current Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Total Current Liabilities data on file, last reported at $40.2 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 5.89% year-over-year to $40.2 million in Q1 2026; TTM through Mar 2026 was $40.2 million, a 5.89% increase from a year earlier, with the FY2025 full-year figure at $38.0 million, down 42.9% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $40.2 million, up from $38.0 million in the prior quarter.
- Over the last five years, Total Current Liabilities for GLAS reached as high as $97.0 million in Q1 2024 and fell as low as $33.2 million in Q3 2025.
- Historically, Total Current Liabilities has averaged $64.6 million across 5 years, with a median of $62.1 million in 2023.
- Across the five-year window, Total Current Liabilities soared 150.9% in 2022 and slumped 60.84% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $54.0 million in 2022, then soared by 61.77% to $87.4 million in 2023, then slipped by 23.9% to $66.5 million in 2024, then tumbled by 42.9% to $38.0 million in 2025, then increased by 5.92% to $40.2 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $40.2 million in Q1 2026, $38.0 million in Q4 2025, and $33.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 599.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 19.22 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 40.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.21 Mn |
| Dec 31, 2025 | 37.96 Mn |
| Sep 30, 2025 | 33.23 Mn |
| Jun 30, 2025 | 43.37 Mn |
| Mar 31, 2025 | 37.97 Mn |
| Dec 31, 2024 | 66.48 Mn |
| Sep 30, 2024 | 82.22 Mn |
| Jun 30, 2024 | 89.91 Mn |
| Mar 31, 2024 | 96.96 Mn |
| Dec 31, 2023 | 87.36 Mn |
| Sep 30, 2023 | 87.55 Mn |
| Jun 30, 2023 | 85.63 Mn |
| Mar 31, 2023 | 62.13 Mn |
| Dec 31, 2022 | 54.00 Mn |
| Sep 30, 2022 | 56.49 Mn |
| Jun 30, 2022 | 75.85 Mn |
| Mar 31, 2022 | 60.79 Mn |
| Dec 31, 2021 | 55.24 Mn |
| Sep 30, 2021 | 60.28 Mn |
| Jun 30, 2021 | 30.23 Mn |